SCHEMBL16039239

SCHEMBL16039239

CCCCC(O)OS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.42
CA9 Q16790 2/20 0.42
CA12 O43570 1/20 0.42
ALDH1A1 P00352 5/20 0.41
LMNA P02545 2/20 0.41
CYP2C9 P11712 2/20 0.41
ALB P02768 1/20 0.41
TSHR P16473 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CNR2 P34972 2/20 0.41
MAPT P10636 2/20 0.40
HTT P42858 2/20 0.40
MCHR1 Q99705 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDM4E B2RXH2 1/20 0.40
PLA2G2C Q5R387 1/20 0.40
CA1 P00915 1/20 0.40
CA4 P22748 1/20 0.40
CA7 P43166 1/20 0.40
CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28122613 0.94 MCHR1 (0.44) CA2CA9CA12ALDH1A1LMNA
SCHEMBL2903624 0.94 MCHR1 (0.44) CA2CA9CA12ALDH1A1LMNA
SCHEMBL1545381 0.90 CA2 (0.47) CA2CA9CA12ALDH1A1LMNA
SCHEMBL1545377 0.90 CA2 (0.47) CA2CA9CA12ALDH1A1LMNA
SCHEMBL1545434 0.90 CA2 (0.47) CA2CA9CA12ALDH1A1LMNA
SCHEMBL7143782 0.88 ALDH1A1 (0.40) CA2CA9CA12ALDH1A1CYP2C9
SCHEMBL11305845 0.86 TDP1 (0.46) CA2CA9ALDH1A1TSHRTDP1
Hydrochloric Acid SCHEMBL9501772 0.85 ALDH1A1 (0.38) CA2CA9CA12ALDH1A1CYP2C9
SCHEMBL5551724 0.84 PPARG (0.41) CA2CA9CA12ALDH1A1CYP2C9
SCHEMBL31344867 0.84 CA12 (0.44) CA2CA9CA12ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970327-B1 OXABICYCLO [2.2.2]ACID GPR120 MODULATORS BRISTOL MYERS SQUIBB CO (US) 2017-05-03 EP disclosed
EP-2970327-A1 OXABICYCLO [2.2.2]ACID GPR120 MODULATORS Bristol-Myers Squibb Company (US) 2016-01-20 EP disclosed
US-8962660-B2 Oxabicyclo [2.2.2] acid GPR120 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2015-02-24 US disclosed
WO-2014151247-A1 OXABICYCLO [2.2.2] ACID GPR120 MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-25 WO disclosed
US-20140275173-A1 OXABICYCLO [2.2.2] ACID GPR120 MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2014-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275173-A1 OXABICYCLO [2.2.2] ACID GPR120 MODULATORS GPR180, GPR52, GPR55 CA2 488/4885CA9 3376/4885CA12 2301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.